Alnylam Pharmaceuticals, Inc. (ALNY) Financial Statements
Alnylam Pharmaceuticals, Inc. (ALNY) reported trailing twelve-month revenue of $4.8B (up 95.1% year on year) and net income of $313.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $819.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ALNYAlnylam Pharmaceuticals, Inc.Follow ALNY — free
—
Price chart with a free account
- Market cap
- 30.0B
- P/E TTM
- 41.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2010 Dec 10 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.10 | 0.07 | 0.22 | 0.49 | 0.84 | 1.04 | 1.83 | 2.25 | 3.71 | 4.80 | |
| Gross profit | — | 0.07 | 0.19 | 0.42 | 0.73 | 0.90 | 1.56 | 1.94 | 3.04 | 3.83 | |
| Research & development | 0.11 | 0.51 | 0.66 | 0.65 | 0.79 | 0.88 | 1.00 | 1.13 | 1.32 | 1.51 | |
| Operating income | -0.04 | -0.81 | -0.94 | -0.83 | -0.71 | -0.79 | -0.28 | -0.18 | 0.50 | 1.00 | |
| Pre-tax income | -0.04 | -0.76 | -0.89 | -0.86 | -0.85 | -1.13 | -0.43 | -0.38 | 0.32 | — | |
| Income tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | -0.10 | 0.01 | -0.01 | |
| Net income | -0.04 | -0.76 | -0.89 | -0.86 | -0.85 | -1.13 | -0.44 | -0.28 | 0.31 | — | |
| Diluted EPS ($) | — | -7.57 | -8.11 | -7.46 | -7.20 | -9.30 | -3.52 | -2.18 | 2.33 | 5.38 | |
| Diluted shares (bn) | — | — | — | — | 0.118 | 0.122 | 0.125 | 0.128 | 0.135 | — |
USD billions · SEC XBRL
Alnylam Pharmaceuticals, Inc. — questions
- What is Alnylam Pharmaceuticals, Inc.'s revenue?
- $4.8B over the twelve months to 2026-06-30, up 95.1% year on year, from its 10-Q and 10-K filings.
- What is Alnylam Pharmaceuticals, Inc.'s net income?
- $313.7M over the twelve months to 2026-06-30.
- What is Alnylam Pharmaceuticals, Inc.'s free cash flow?
- $819.9M over the twelve months to 2026-06-30.
- What are Alnylam Pharmaceuticals, Inc.'s diluted earnings per share?
- $5.38 over the twelve months to 2026-06-30.
Every figure on this page comes from Alnylam Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.